| 1 |
27027531 | IFNL4 polymorphism effects on outcome of simeprevir, peginterferon, and ribavirin therapy for older patients with genotype 1 chronic hepatitis C. | 2017 Mar |
1 |
| 2 |
28506030 | Simeprevir-Based Triple Therapy with Reduced Doses of Pegylated Interferon α-2a Plus Ribavirin for Interferon Ineligible Patients with Genotype 1b Hepatitis C Virus. | 2017 Jul 15 |
4 |
| 3 |
26857426 | Successful achievement of sustained virological response to triple combination therapy containing simeprevir in two patients with chronic hepatitis C who had failed asunaprevir:Daclatasvir combination therapy. | 2016 Oct |
2 |
| 4 |
28635836 | [Possibilities of using cepeginterferon alpha-2b in double (cepeginterferon alfa-2b and ribavirin) and triple (simeprevir, cepeginterferon alpha-2b, and ribavirin) antiviral therapy regimens for chronic hepatitis C. A review of clinical trials and experience of everyday clinical practice]. | 2016 |
1 |
| 5 |
24961662 | Simeprevir (TMC435) once daily with peginterferon-α-2b and ribavirin in patients with genotype 1 hepatitis C virus infection: The CONCERTO-4 study. | 2015 May |
2 |
| 6 |
25529083 | How to optimize current therapy in hepatitis C virus genotype 1 patients. Predictors of response to interferon-based therapy with second wave direct acting antivirals. | 2015 Jan |
2 |
| 7 |
25624738 | Simeprevir with peginterferon and ribavirin induced interstitial pneumonitis: first case report. | 2015 Jan 21 |
3 |
| 8 |
25963122 | Mycophenolate mofetil may induce prolonged severe anemia during pegylated-interferon/ribavirin/simeprevir therapy in liver transplant recipients. | 2015 Jun |
1 |
| 9 |
26075320 | Effectiveness of triple therapy with simeprevir for chronic hepatitis C genotype 1b patients with prior telaprevir failure. | 2015 Dec |
2 |
| 10 |
24373080 | Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir. | 2014 Feb |
1 |
| 11 |
24373081 | HCV direct-acting antiviral agents: the best interferon-free combinations. | 2014 Feb |
1 |
| 12 |
24677184 | Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals. | 2014 Jul |
1 |